Division of Public Health.
Decision Sciences Institute.
J Consult Clin Psychol. 2019 Apr;87(4):392-406. doi: 10.1037/ccp0000379. Epub 2019 Feb 4.
This study tested the effectiveness and cost-effectiveness of interpersonal psychotherapy (IPT) for major depressive disorder (MDD) among prisoners. It is the first fully powered randomized trial of any treatment (pharmacological or psychosocial) targeting MDD among incarcerated individuals.
One hundred eighty-one male (n = 117) and female (n = 64) prisoners from prison facilities in 2 states were randomized to group IPT (delivered by master's-level and nonspecialist prison counselors) for MDD plus prison treatment as usual (TAU) or to TAU alone. Participants' average age was 39 (range = 20-61); 20% were African American and 19% were Hispanic. Outcomes assessed at posttreatment and 3-month follow-up included depressive symptoms (primary; assessed using the Hamilton Rating Scale for Depression), suicidality (assessed with the Beck Scale for Suicide Ideation and Beck Hopelessness Scale), in-prison functioning (i.e., enrollment in correctional programs; discipline reports; aggression/victimization; and social support), remission from MDD, and posttraumatic stress disorder symptoms.
IPT reduced depressive symptoms, hopelessness, and posttraumatic stress disorder symptoms, and increased rates of MDD remission relative to prison TAU alone. Effects on hopelessness were particularly strong. Cost per patient was $2,054 including costs for IPT training and supervision or $575 without these costs. For providers running their second or subsequent IPT group, cost per additional week in remission from MDD (relative to TAU alone) was $524 ($148 excluding training and supervision costs, which would not be needed for established programs).
IPT is effective and cost-effective and we recommend its use for MDD among prisoners. It is currently the only treatment for MDD evaluated among incarcerated individuals. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
本研究旨在检验人际心理治疗(IPT)对囚犯中重度抑郁障碍(MDD)的有效性和成本效益。这是首个针对被监禁个体中 MDD 的任何治疗(药物或心理社会)的全功率随机试验。
181 名男性(n=117)和女性(n=64)囚犯来自 2 个州的监狱设施,被随机分为 IPT 组(由硕士水平和非专业监狱顾问提供)治疗 MDD,加监狱常规治疗(TAU),或仅 TAU 组。参与者的平均年龄为 39 岁(范围=20-61);20%为非裔美国人,19%为西班牙裔。治疗后和 3 个月随访评估的结果包括抑郁症状(主要结果;使用汉密尔顿抑郁评定量表评估)、自杀意念(贝克自杀意念量表和贝克绝望量表评估)、监狱功能(即参加矫正项目;纪律报告;攻击/受害;和社会支持)、MDD 缓解和创伤后应激障碍症状。
IPT 降低了抑郁症状、绝望感和创伤后应激障碍症状,提高了 MDD 缓解率,优于监狱 TAU 单独治疗。对绝望感的影响尤其强烈。包括 IPT 培训和监督费用在内,每位患者的费用为 2054 美元,不包括这些费用则为 575 美元。对于运营第二次或后续 IPT 小组的提供者来说,相对于 TAU 单独治疗,每周额外缓解 MDD 的成本为 524 美元(不包括培训和监督费用,这些费用对于成熟的项目来说是不需要的)。
IPT 是有效且具有成本效益的,我们建议在囚犯中使用它治疗 MDD。它是目前唯一在被监禁个体中评估的 MDD 治疗方法。(APA,2019,所有权利保留)。